Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01359605 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects
A Phase 1 study, sponsored by Anthera Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01359605: Completed Phase 1 study, sponsored by Anthera Pharmaceuticals.
NCT01359605 is a Phase 1 study that has completed, run by Anthera Pharmaceuticals. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01359605, a Phase 1 study, has completed, sponsored by Anthera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to characterize the metabolism and excretion (ADME) of a single oral dose of \[14C\]varespladib methyl.
Interventions
- DRUG varespladib methyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
What the finished NCT01359605 record still lists
NCT01359605 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which varespladib methyl is the first listed.
NCT01359605 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01359605 about?
NCT01359605 is a clinical study titled "Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects". The purpose of the study is to characterize the metabolism and excretion (ADME) of a single oral dose of \[14C\]varespladib methyl.
What is the current status of trial NCT01359605?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-06. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01359605?
The interventions under investigation include: varespladib methyl (DRUG).
Who is sponsoring clinical trial NCT01359605?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01359605's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia